At the end of September, the European Society of Cardiology issued a scientific publication stating that the administration of HCQ is safe for a short-term treatment for patients with COVID-19 infection, regardless of the clinical setting of delivery, causing only modest prolongation and no directly attributable arrhythmic deaths, which fully confirms BCI’s results.
Read the full interview here in Bulgarian.